[Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke].
Miasoedova. N F NF; Skvortsova. V I VI; Nasonov. E L EL; Zhuravleva. E Iu EIu; Grivennikov. I A IA; Arsen'eva. E L EL; Sukhanov. I I II
Key Findings
- Semax demonstrated angioprotective, antihypoxic, and neurotrophic effects in rodent stroke models at 100‑150 µg/kg.
- Clinical‑electrophysiologic data indicated high efficacy of semax when given in the acute phase of ischemic stroke.
- Molecular analysis showed semax increased anti‑inflammatory markers (IL‑10, TNF‑α) and decreased pro‑inflammatory markers (IL‑8, CRP).
Practical Outcomes
- For biohackers, semax may be worth exploring as a neuroprotective supplement, especially for people at risk of cerebrovascular events. The data suggest an anti‑inflammatory mechanism, but human dosing protocols are not yet established, so cautious, low‑dose experimentation (e.g., sub‑microgram per kg ranges) and medical supervision are advised. It is not a proven longevity or performance enhancer, but could be part of a broader brain‑health stack.
Summary
The study shows that semax, a peptide nootropic, can help protect the brain after a stroke by shifting the immune response toward anti‑inflammatory signals. In animal tests, doses of 100‑150 µg per kilogram reduced damage, and early human data suggest it may improve outcomes in acute ischemic stroke.
Abstract
Semax is the first domestic nootropic drug of an unexhausted type from the group of neuropeptides. In experimental studies it showed angioprotective, antihypoxic and neurotrophic activity in the doses 100-150 micrograms/kg. A combined clinical-electrophysiologic study revealed its high efficiency in acute ischemic stroke. A clinical trial was performed of immunobiochemical mechanisms of neuroprotective properties of Semax in acute period of ischemic stroke. A retrospective comparative clinicoimmunobiochemical analysis provided objective data on the molecular level on activating influence of Semax on antiinflammatory postischemic reactions in the brain. Shifting neuromediatory balance toward a prevalence of the antiinflammatory agents (interleukin-10, tumor necrosis factor-alpha) over the factors maintaining the inflammation (interleukin-8, C-reactive protein).
Study Information
pubmed
1999